Sandbox me: Difference between revisions

Jump to navigation Jump to search
Line 53: Line 53:
::::* Alternative regimen (6): [[Atovaquone]] 1500 mg  PO {{and}} [[Pyrimethamine]] 25 mg {{and}} [[Leucovorin]] 10 mg PO qd
::::* Alternative regimen (6): [[Atovaquone]] 1500 mg  PO {{and}} [[Pyrimethamine]] 25 mg {{and}} [[Leucovorin]] 10 mg PO qd


==Varicella zoster==
==Varicella zoster==
:* 1. '''Varicella zoster'''
:* 1. '''Varicella zoster'''
::* 1.1 '''Non Immunocompromised person'''
::* 1.1 '''Non Immunocompromised person'''
Line 79: Line 79:
:::* Preferred regimen: [[Acyclovir]] IV  10–15 mg/kg q8h for 10–14 days followed by [[Valacyclovir]]  PO 1 g tid  daily for 4–6 weeks
:::* Preferred regimen: [[Acyclovir]] IV  10–15 mg/kg q8h for 10–14 days followed by [[Valacyclovir]]  PO 1 g tid  daily for 4–6 weeks


:::*Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-Infected Adults and Adolescents
:::* '''Recommendations for treating varicella zoster virus (VZV) Infections in HIV-Infected adults and adolescents'''
:::*Treatment of Varicella Infections
:::* '''Treatment of Varicella Infections'''
:::*Primary Varicella Infection (Chickenpox)
:::* '''Primary Varicella Infection (Chickenpox)'''
:::*Uncomplicated Cases
:::* '''Uncomplicated Cases'''
:::* Preferred regimen:Valacyclovir 1 g PO TID for 5–7 days  
:::* Preferred regimen:[[Valacyclovir]] 1 g PO tid for 5–7 days  
:::* Preferred regimen: Famciclovir 500 mg PO TID for 5–7 days
:::* Preferred regimen: [[Famciclovir]] 500 mg PO tid  for 5–7 days
:::*Alternative Therapy:Acyclovir 800 mg PO 5 times daily for 5–7 days
:::* Alternative regimen: [[Acyclovir]] 800 mg PO 5 times daily for 5–7 days
 
:::* '''Severe or Complicated Cases'''
:::*Severe or Complicated Cases:
:::* Preferred regimen: [[Acyclovir]] 10–15 mg/kg IV q8h for 7–10 days  
:::* Preferred regimen:Acyclovir 10–15 mg/kg IV q8h for 7–10 days (AIII)
:::* Note: May switch to oral [[Famciclovir]], [[Valacyclovir]], or [[Acyclovir]] after defervescence if no evidence of visceral involvement is evident
:::*May switch to oral famciclovir, valacyclovir, or acyclovir after defervescence if no evidence of visceral involvement is evident (BIII)
:::* '''Herpes Zoster (Shingles)'''
:::*Herpes Zoster (Shingles)
:::* '''Acute Localized Dermatomal'''
:::*Acute Localized Dermatomal
:::* Preferred regimen: [[Valacyclovir]] 1000 mg PO tid for 7–10 days
:::*Preferred Therapy:
:::* Preferred regimen: [[Famciclovir]] 500 mg PO tid for 7–10 days
:::* Preferred regimen:Valacyclovir 1000 mg PO TID for 7–10 days
:::*Alternative Therapy: [[Acyclovir]] 800 mg PO 5 times daily for 7–10 days
:::* Preferred regimen:Famciclovir 500 mg PO TID for 7–10 days
:::*  longer duration should be considered if lesions resolve slowly
:::*Alternative Therapy: Acyclovir 800 mg PO 5 times daily for 7–10 days
Duration:
for 7–10 days, longer duration should be considered if lesions resolve slowly


:::*Extensive Cutaneous Lesion or Visceral Involvement
:::*Extensive Cutaneous Lesion or Visceral Involvement

Revision as of 19:22, 27 July 2015

Toxoplasmosis

  • Toxoplasma gondii (treatment)
  • 1. Lymphadenopathic toxoplasmosis[1]
  • Preferred regimen: Treatment of immunocompetent adults with lymphadenopathic toxoplasmosis is rarely indicated; this form of the disease is usually self-limited.
  • 2. Ocular disease[2]
  • 2.1 Adults
  • 2.2 Pediatric
  • Preferred regimen: Pyrimethamine 2 mg/kg PO first day then 1 mg/kg each day AND Sulfadiazine 50 mg/kg PO bid AND folinic acid (Leucovorin 7.5 mg/day PO ) for 4 to 6 weeks followed by reevaluation of the patient's condition
  • Alternative regimen: The fixed combination of Trimethoprim with Sulfamethoxazole has been used as an alternative.
  • Note: If the patient has a hypersensitivity reaction to sulfa drugs, Pyrimethamine AND Clindamycin can be used instead.
  • 3. Maternal and fetal infection[3]
  • 3.1 First and early second trimesters
  • 3.2 Late second and third trimesters
  • 3.3 Infant
  • 4. Toxoplasma gondii Encephalitis in AIDS[4]
  • 4.1 Treatment for acute infection
  • 4.2 Chronic maintenance therapy
  • Preferred regimen: Pyrimethamine 25–50 mg PO qd AND sulfadiazine 2000–4000 mg PO qd (in 2–4 divided doses) AND Leucovorin 10–25 mg PO qd
  • Alternative regimen (1): Clindamycin 600 mg PO q8h AND (Pyrimethamine 25–50 mg AND Leucovorin 10–25 mg) PO qd
  • Alternative regimen (2): TMP-SMX DS 1 tablet bid
  • Alternative regimen (3): Atovaquone 750–1500 mg PO bid AND (Pyrimethamine 25 mg AND Leucovorin 10 mg) PO qd
  • Alternative regimen (4): Atovaquone 750–1500 mg PO bid
  • Alternative regimen (5): Sulfadiazine 2000–4000 mg PO bid/qid
  • Alternative regimen (6): Atovaquone 750–1500 mg PO bid Pyrimethamine and Leucovorin doses are the same as for preferred therapy
  • Note: Adjunctive corticosteroids (e.g., Dexamethasone) should only be administered when clinically indicated to treat mass effect associated with focal lesions or associated edema; discontinue as soon as clinically feasible. Anticonvulsants should be administered to patients with a history of seizures and continued through acute treatment, but should not be used as seizure prophylaxis . If Clindamycin is used in place of Sulfadiazine, additional therapy must be added to prevent PCP.
  • Toxoplasma gondii (prophylaxis)
  • 1. Prophylaxis to prevent first episode of encephalitis in AIDS[5]
  • 1.1 Indications
  • Toxoplasma IgG-positive patients with CD4 count <100 cells/µL
  • Seronegative patients receiving PCP prophylaxis not active against toxoplasmosis should have toxoplasma serology retested if CD4 count decline to <100 cells/µL. Prophylaxis should be initiated if seroconversion occurred.
  • 1.2 Prophylactic therapy
==Varicella zoster==
  • 1. Varicella zoster
  • 1.1 Non Immunocompromised person
  • Preferred regimen (1): Acyclovir 500 mg PO five times daily for 7-10 days
  • Preferred regimen (2):Famciclovir 500 mg PO tid daily for 7 days
  • Preferred regimen (3):Valacyclovir 1 g PO tid daily for 7 days
  • Preferred regimen (4): Brivudin125 mg PO qd daily for 7 days
  • 1.2 Immunocompromised person requiring hospitalization or persons with sever neurologic complications
  • Preferred regimen (1): Acyclovir 10 mg/ kg IV q8h for 7-10 days
  • Preferred regimen (2):Foscarnet 40 mg/ kg IV q8h until lesions are healed
  • Note (1): Brivudin is not available in USA and has not been approved by FDA
  • Note (2): Foscarnet is not approve by FDA
  • Treatment of VZV complications
  • HZ ophthalmicus
  • Treatment includes the following
  • (1) Famciclovir or Valacyclovir for 7–10 days, preferably started within 72 h of rash onset (with IV Acyclovir given as needed for retinitis), to resolve acute disease and inhibit late inflammatory recurrences
  • (2) pain medications,
  • (3) cool to tepid wet compresses (if tolerated);
  • (4) antibiotic ophthalmic ointment administered bid (e.g.Bacitracin-Polymyxin), to protect the ocular surface;
  • (5) topical steroids (e.g., 0.125%–1% Prednisolone 2–6 times daily) prescribed and managed only by an ophthalmologist for corneal immune disease, episcleritis, scleritis, or iritis;
  • (6) no topical antivirals, because they are ineffective;
  • (7) mydriatic/cycloplegia as needed for iritis (e.g., 5% Homatropine bid
  • (8) ocular pressure–lowering drugs given as needed for glaucoma (e.g., Latanaprost qd and/or Timolol maleate ophthalmic gel forming solution every morning). Systemic steroids are indicated in the presence of moderate to severe pain or rash, particularly if there is significant edema, which may cause orbital apex syndrome through pressure on the nerves entering the orbit. The dosage is commonly 20 mg of Prednisone administered (together with an oral antiviral agent) PO tid for 4 days,bid for 6 days, and then once daily every morning for 4 day
  • VZV retinitis
  • Preferred regimen: Acyclovir IV 10–15 mg/kg q8h for 10–14 days followed by Valacyclovir PO 1 g tid daily for 4–6 weeks
  • Recommendations for treating varicella zoster virus (VZV) Infections in HIV-Infected adults and adolescents
  • Treatment of Varicella Infections
  • Primary Varicella Infection (Chickenpox)
  • Uncomplicated Cases
  • Preferred regimen:Valacyclovir 1 g PO tid for 5–7 days
  • Preferred regimen: Famciclovir 500 mg PO tid for 5–7 days
  • Alternative regimen: Acyclovir 800 mg PO 5 times daily for 5–7 days
  • Severe or Complicated Cases
  • Preferred regimen: Acyclovir 10–15 mg/kg IV q8h for 7–10 days
  • Note: May switch to oral Famciclovir, Valacyclovir, or Acyclovir after defervescence if no evidence of visceral involvement is evident
  • Herpes Zoster (Shingles)
  • Acute Localized Dermatomal
  • Preferred regimen: Valacyclovir 1000 mg PO tid for 7–10 days
  • Preferred regimen: Famciclovir 500 mg PO tid for 7–10 days
  • Alternative Therapy: Acyclovir 800 mg PO 5 times daily for 7–10 days
  • longer duration should be considered if lesions resolve slowly
  • Extensive Cutaneous Lesion or Visceral Involvement
  • Preferred regimen:Acyclovir 10–15 mg/kg IV q8h until clinical improvement is evident (AII)
  • Switch to oral therapy (valacyclovir 1 g TID, famciclovir 500 mg TID, or acyclovir 800 mg PO 5 times daily)—to complete a 10–14 day course, when formation of new lesions has ceased  :::*signs :::*and symptoms of visceral VZV infection are improving (BIII)
  • PORN
  • Involvement of an experienced ophthalmologist is strongly recommended (AIII)
  • Preferred regimen:Ganciclovir 5 mg/kg and/or foscarnet 90 mg/kg IV q12h plus ganciclovir 2 mg/0.05mL and/or foscarnet 1.2 mg/0.05mL intravitreal twice weekly (AIII)
  • Optimize ART regimen (AIII)
  • Duration of therapy is not well defined and should be determined based on clinical, virologic, and immunologic response in consultation with ophthalmologist.
  • Note: ganciclovir ocular implants are no longer commercially available
  • ARN
  • Preferred regimen:Acyclovir 10-15 mg/kg IV q8h for 10–14 days, followed by valacyclovir 1 g PO TID for 6 weeks PLUS ganciclovir 2 mg/0.05mL intravitreal twice weekly X 1-2 doses (AIII)
  • Involvement of an experienced ophthalmologist is strongly recommended (AIII)
  • Duration of therapy is not well defined and should be determined based on clinical, virologic, and immunologic response in consultation with ophthalmologist.

Influenza

  • 1. Adults
  • Preferred regimen (1): Oseltamivir (Tamiflu®) 75 mg bid
  • Preferred regimen (2): Zanamivir (Relenza®) 10 mg (two 5-mg inhalations) bid
  • Preferred regimen (3): Peramivir (Rapivab®) 600 mg IV for 15-30 minutes (single dose)
  • Note: FDA approved and recommended Peramivir (Rapivab®) for use in adults ≥18 yrs
  • 2. Children
  • 2.1 < 1 yr
  • Preferred regimen: Oseltamivir (Tamiflu®) 3 mg/kg/dose bid
  • 2.2 > 1 yr
  • 2.2.1 ≤ 15 kg
  • 2.2.2 > 15 to 23 kg
  • 2.2.3 > 23 to 40 kg
  • 2.2.4 > 40 kg
  • Preferred regimen: Oseltamivir (Tamiflu®) 75 mg bid
  • Note: Zanamivir (Relenza®) 10 mg (two 5-mg inhalations) bid may be considered for children > 7 yrs old
  • Adult Patients with Renal Impairment or End Stage Renal Disease (ESRD) on Dialysis
  • Oral Oseltamivir
  • Creatinine clearance 61 to 90 mL/min-75 mg twice a day
  • Creatinine clearance 31 to 60 mL/min-30 mg twice a day
  • Creatinine clearance 10 to 30 mL/min-30 mg once daily
  • ESRD Patients on Hemodialysis
  • Creatinine clearance ≤10 mL/min-30 mg after every hemodialysis cycle. Treatment duration not to exceed 5 days
  • ESRD Patients on Continuous Ambulatory Peritoneal Dialysis-A single 30 mg dose administered immediately after a dialysis exchange
  • Intravenous Peramivir (single dose)
  • Creatinine clearance >50 mL/min-600mg
  • Creatinine clearance 30 to 49 mL/min-200mg
  • Creatinine clearance 10 to 29 mL/min-100mg
  • ESRD Patients on Hemodialysis-Dose administered after dialysis at a dose adjusted based on creatinine clearance




Children- < 1 yr: 3 mg/kg/dose twice daily > 1 yr: dose depends on weight. ≤ 15 kg: 30 mg twice a day > 15 to 23 kg: 45 mg twice a day > 23 to 40 kg: 60 mg twice a day > 40 kg: 75 mg twice a day.

Zanamivir (Relenza®) Adults 10 mg (two 5-mg inhalations) twice daily

For children > 7 yrs old. 10 mg (two 5-mg inhalations) twice daily


Peramivir (Rapivab®) Adults 600 mg IV for 15-30 minutes (single dose)

  1. "Parasites - Toxoplasmosis (Toxoplasma infection)".
  2. "Parasites - Toxoplasmosis (Toxoplasma infection)".
  3. "Parasites - Toxoplasmosis (Toxoplasma infection)".
  4. "Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents" (PDF).
  5. "Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents" (PDF).